HOUSTON--Texas Biotechnology, a company here specializing in computer-aided small-molecule drug design, has reported third-quarter results that show nearly a nine-fold increase in revenue compared to the same period last year. That's largely because of an $8.5 million license fee that came from a corporate partnership with SmithKline Beecham. In addition, operating expenses for the quarter fell compared to the same period last year.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.